Matinas BioPharma Holdings, Inc.MTNBEarnings & Financial Report
NYSE
MTNB Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-1.6M
Net Profit
$-1.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.40
Matinas BioPharma Holdings, Inc. Q3 2025 Financial Summary
Matinas BioPharma Holdings, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-1.5M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-1.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Matinas BioPharma Holdings, Inc. Annual Revenue by Year
Matinas BioPharma Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $1.1M |
| 2022 | $3.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $25.1M | $19.6M | $24.4M | $20.6M | $12.6M | $12.0M | $11.4M | $9.7M |
| Liabilities | $5.9M | $5.1M | $5.3M | $4.8M | $5.1M | $5.8M | $3.7M | $3.2M |
| Equity | $19.2M | $14.6M | $19.1M | $15.8M | $7.6M | $6.3M | $7.7M | $6.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.6M | $-5.8M | $-3.1M | $-3.5M | $-3.5M | $-2.0M | $-2.0M | $-1.5M |